This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Acadia (ACAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Acadia (ACAD) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
QGEN vs. ACAD: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
by Kanishka Das
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
by Zacks Equity Research
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
by Zacks Equity Research
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
by Zacks Equity Research
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
GMAB vs. ACAD: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KMDA or ACAD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
KMDA vs. ACAD: Which Stock Is the Better Value Option?
KMDA vs. ACAD: Which Stock Is the Better Value Option?
by Zacks Equity Research
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK or ACAD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. ACAD: Which Stock Is the Better Value Option?
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?